Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic HSCT with Sirolimus and Th2 Cells for Hematologic Malignancies
NCT00074490Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jan 2004
- Primary completion
- Jul 2017
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sirolimus-generated donor Th2 cells in leukemia, lymphoma, multiple myeloma (MM) and 2 more (3 cohorts), sponsored by National Cancer Institute. Primary endpoints: Percentage of Patients to Receive T Cell Infusion at 100 days and Percentage of Patients With ≥ Grade 2 Acute Graft Versus Host Disease (GVHD) at 100 days. Started Jan 2004; status: terminated.
02
Drugs
sirolimus-generated donor Th2 cells
03
Conditions
leukemialymphomamultiple myeloma (MM)myelodysplastic syndrome (MDS)myeloproliferative neoplasms (MPN)
Beyond the preview
Go deeper on NCT00074490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00074490.